This report aims to explore the events and trends of the biopharmaceutical industry in Q2 (April, May, June). Besides crovalimab and Vyloy, two more novel antibody drugs have been approved this year:
-
Tarlatamab (Imdelltra), a bispecific antibody treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
-
Seniprutug (Tribuvia), a monoclonal antibody drug for ankylosing spondylitis, also known as axial spondyloarthritis or Bechterew-Strümpell syndrome.
This quarter saw notable progress in antibody drug discovery with machine learning, particularly with the advancements in generative AI, reducing development timelines and increasing the efficiency of targeting complex diseases. We delve into three companies to watch who are using AI for antibody drug discovery.
Q2 2024 witnessed major deals and acquisitions of up to $3 billion USD in value. Investment in antibodies is also continuing, with startup launches of up to $1 billion USD focused on AI, diseases such as obesity, and next-generation formats like antibody-peptide conjugates (APCs). We highlight three APCs currently in development, as well as weight-loss antibody medications.
There are several exciting antibodies to watch in Q3 which are either in regulatory review or in late-stage clinical trials. These antibodies range from those treating cancers to COVID-19 and skin diseases.
Register now for a free download of the report!
Register to access the full report produced by Biointron
